Status: Not yet recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.
Participants needed: 600
Trial details
Phase: Phase 4Age: 40+Biological sex: AllType: InterventionalSponsor: Changchun BCHT Biotechnology Co.Updated: May 8, 2025
Eligibility criteria
Age ≥40 years on enrollment day； [+3]
People who are immune deficient or immunosuppressed due to certain diseases or t... [+10]